Back    Zoom +    Zoom -
CANBRIDGE-B Leaps 5%+ After Announcing 14.7% Discounted Shr Placement to WUXI BIO's Subsidiary
Recommend
1
Positive
0
Negative
2
CANBRIDGE-B (01228.HK) announced the placement of 84.0336 million shares (around 14.12% of the enlarged share capital) to WuXi Biologics HealthCare Venture, a subsidiary of WUXI BIO (02269.HK), at a price of HKD2.38 per share, a 14.7% discount to the closing price of HKD2.79 on February 13.

The total fundraising from this placement will amount to HKD200 million, with net proceeds of around HKD199 million.

Related NewsJPM Raises WUXI BIO (02269.HK) TP to $51 on Profit Alert Beat, Strong Order Momentum
CANBRIDGE-B opened 3.23% higher today and once peaked at HKD2.93. It last traded at HKD2.93, up 5.02%, with a volume of 20,000 shares, involving HKD57,700.
AAStocks Financial News